Tag: Cancer: Brain

FastGlioma outperformed image-guided and fluorescence-guided adjuncts in a head-to-head prospective study

74 percent of patients had the same changes from pretreatment to posttreatment with T1 + contrast and MRI-linac lesions

Slowed development of academic readiness predictive of distal academic outcomes in reading, math

This is the first FDA-approved systemic therapy for patients with a susceptible IDH1 or IDH2 mutation

Risk for subsequent development of brain cancer increased in cohort of mostly male veterans

CHARM can also distinguish isocitrate dehydrogenase-mutant tumors from wild type, and classify three types of molecularly defined gliomas

Several tumor and treatment factors were tied to risk for poorer outcomes

Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo

Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood

GD2-targeted CAR T cells expanded in vivo, and were detectable in peripheral blood up to 30 months after infusion